Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [6][26]. Core Insights - The report emphasizes the continuous recommendation of innovative pharmaceuticals and medical devices, highlighting the high growth potential in the sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also recommends Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][3]. Summary by Sections 1. Continuous Recommendation of Innovative Pharmaceuticals and Medical Devices - The report highlights the high growth potential of innovative drugs and recommends several companies for investment, including Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also suggests Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][7]. 2. A-share Pharmaceutical Sector Performance - In the third week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index declining by 0.4% and the SW Pharmaceutical and Biotech index falling by 0.7% [8][11]. 3. Hong Kong and US Market Performance - The Hong Kong pharmaceutical sector performed in line with the market, while the US pharmaceutical sector underperformed. In the same week, the Hang Seng Healthcare index rose by 2.4%, and the S&P 500 healthcare sector fell by 1.1% [19][20].

近日，由国家传染病医学中心、中华医学会感染病学分会及《中华传染病杂志》编辑委员会共同制定的 《中国高危人群乙型肝炎病毒再激活防治指南(2026年版)》(以下简称：《指南》)正式发布，为我国高 危人群乙型肝炎病毒(HBV)再激活的管理提供了系统、权威的循证实践指导建议。翰森制药自主研发的 中国首个原研口服抗乙型肝炎病毒药物——艾米替诺福韦(恒沐，TMF)作为新一代核苷(酸)类HBV抗病 毒药物，在《指南》中被明确列为预防HBV再激活的推荐用药之一。 HBV再激活是临床上面临的重要问题，尤其在接受免疫抑制治疗、免疫检查点抑制剂、嵌合抗原受体T 细胞治疗(CAR-T)以及器官移植等高危人群中，可能导致肝炎活动甚至肝衰竭，危及生命。因此，科 学、规范的药物预防至关重要。《指南》基于国内外最新循证证据，结合中国临床实际，对不同免疫抑 制方案下的预防策略进行了系统梳理与推荐，具有重要的临床指导价值。 其中，关于"选择哪种抗病毒药物预防乙肝病毒再激活？"这一临床问题，《指南》推荐选择高耐药基因 屏障药物进行预防性抗乙肝病毒治疗，并列举了包括艾米替诺福韦在内的几种核苷(酸)类药物，推荐等 级为强推荐，且证据质量高。 上市以来 ...

Group 1 - The core viewpoint of the news highlights the performance and trends of the Hong Kong innovative drug sector, particularly focusing on the Hong Kong Stock Connect Innovative Drug ETF (159570), which has seen significant capital inflow and is leading in scale among similar funds [1][2] - The 44th JPMorgan Healthcare Conference showcased several Chinese innovative pharmaceutical companies, emphasizing trends in gene and cell therapy, as well as AI in medicine, indicating a shift from "assets being bought" to "global value" for Chinese innovations [1][2] - The innovative drug sector is expected to reach new highs due to various catalysts, including the significant valuation gap between China and the US, ongoing business development (BD) transactions, and low current allocation of pharmaceutical theme funds in the market [2] Group 2 - Major stocks within the Hong Kong Stock Connect Innovative Drug ETF mostly experienced declines, with notable drops exceeding 1% for companies like BeiGene, China Biologic Products, and others, while CSPC Pharmaceutical showed a slight increase [2][3] - Key innovative drugs presented at the JPMorgan Conference include BeiGene's CDK4 products and the first BCL2 inhibitor approved in China, which highlights the competitive landscape and advancements in treatment options for various cancers [5][6] - The collaboration between Rongchang Biopharmaceutical and AbbVie on the PD-1/VEGF dual antibody RC148 is a significant development, with potential milestone payments and royalties, showcasing the growing internationalization of Chinese innovative drugs [9][10]

Core Insights - The JPM Healthcare Conference 2026 highlighted a significant shift in the narrative surrounding Chinese innovation assets, which are increasingly recognized as critical components for multinational pharmaceutical companies' long-term growth strategies [4][5][24] - The conference emphasized the importance of clinical advancement efficiency and global development pace for Chinese pharmaceutical companies, marking the entry of their innovation pipelines into the core narratives of multinational firms as just the beginning [24] Group 1: Chinese Companies' Innovations - Chinese companies are now being integrated into the core strategies of multinational pharmaceutical firms, moving beyond previous "single-point licensing" narratives to being key contributors in oncology, neuroscience, and metabolic diseases [5][9] - Notable collaborations include SystImmune's BL-B01D1, which has a potential total deal value of $800 million with Bristol-Myers Squibb, and the KarXT project, which is prioritized for development in the psychiatric pipeline [5][7] - The partnership between 3SBio and Pfizer on the PD-1 and VEGF bispecific antibody SSGJ-707 is highlighted as a significant transaction, indicating its strategic importance in the next-generation oncology immunotherapy landscape [7][9] Group 2: Multinational Companies' Strategies - Multinational companies are focusing on a 2030 pricing framework, with strategic decisions revolving around which assets will shape the next industry reshuffle [10][24] - Bristol-Myers Squibb plans to launch 10 new drugs by 2030, emphasizing a multi-pillar approach to mitigate risks associated with patent cliffs [10][12] - Vertex Pharmaceuticals and Madrigal Pharmaceuticals are adopting a focused strategy on single disease areas, with Madrigal positioning itself as a leader in the MASH field and Vertex concentrating on cystic fibrosis and gene therapy [12][15] Group 3: Market Dynamics and Challenges - The second day of the conference shifted focus to practical execution challenges, including competition in metabolic diseases, patent expirations, and supply chain management [16][24] - Eli Lilly expressed uncertainty regarding the market performance of its oral GLP-1 candidate, while Novo Nordisk acknowledged significant competitive pressures and emphasized direct patient channel management [16][18] - Bayer updated its assessment of patent expirations for Xarelto and Eylea, indicating a gradual approach to managing revenue impacts while relying on new product launches for future growth [18][19] Group 4: Supply Chain and Manufacturing - The importance of local manufacturing capabilities was underscored, with Samsung Biologics discussing its U.S. production capacity to meet growing demand [21][24] - Companies like Teva and Sandoz are focusing on the strategic value of biosimilars in light of upcoming patent expirations, indicating a long-term structural adjustment rather than a short-term fix [19][21]

Core Insights - Hansoh Pharmaceutical Group Limited announced the approval of a fifth indication for Amelotex (Ametinib Mesylate Tablets), which is now indicated for first-line treatment in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations [1][2] Group 1: Product Approval and Clinical Data - The approval is based on the AENEAS 2 Phase III clinical study, which demonstrated that Amelotex combined with chemotherapy significantly extends progression-free survival (PFS) compared to monotherapy, with a hazard ratio (HR) of 0.47, indicating a 53% reduction in the risk of disease progression or death [1] - The median PFS was extended to 28.9 months, with an objective response rate (ORR) of 93.2%, and no new safety risks were identified [1] - The study included only Chinese patients, highlighting the efficacy and safety of the original EGFR-TKI in this demographic [1] Group 2: Product Background and Market Position - Amelotex is the first original third-generation EGFR-TKI in China, approved for five indications since its initial launch in March 2020 [2][3] - Previous indications include postoperative adjuvant therapy for EGFR mutation NSCLC, maintenance therapy after chemoradiotherapy for unresectable locally advanced NSCLC, and first-line and second-line treatments for advanced NSCLC [2] - The drug has established a strong clinical position in treating lung cancer in China, providing high-level evidence for its use [2] Group 3: Company Overview - Hansoh Pharmaceutical is a leading innovation-driven pharmaceutical company in China, focusing on major disease areas such as oncology, anti-infection, central nervous system, metabolism, and autoimmune diseases [4] - The company has a strong revenue stream from innovative drugs, with over 80% of its income derived from this segment, and has established a rich R&D pipeline [4] - Hansoh Pharmaceutical has been recognized as one of the top global pharmaceutical companies and is listed on the Hong Kong Stock Exchange under the stock code 03692.HK [4]

Group 1 - The Chinese government has extended the personal income tax refund policy for home purchases until December 31, 2027, which aims to stimulate the real estate market by allowing tax refunds based on the sale and purchase amounts of properties [3][3][3] - The U.S. State Department announced a suspension of visa processing for 75 countries, effective January 21, as part of a reevaluation of screening and review processes [3][3][3] - The U.S. has imposed a 25% tariff on certain imported semiconductors and related products, effective January 15, as part of its trade policy [4][4][4] Group 2 - OpenAI has signed a three-year agreement with Cerebras to procure up to 750 megawatts of computing power, with the total deal exceeding $10 billion, focusing on AI chip technology [7][8][8] - Skild AI has completed a $1.4 billion financing round, raising its valuation to over $14 billion, with participation from major investors including SoftBank and Nvidia [25][25] - Proxima, an AI biotechnology company, has secured $80 million in seed funding, led by DCVC, to advance its research and development efforts [26][26][26] Group 3 - The Chinese smartphone market is projected to see Huawei regain the top position by 2025, with an estimated total shipment of 285 million units, reflecting a slight decline of 0.6% year-on-year [22][22][22] - The private equity firm, Huanfang Quantitative, reported a 56.6% average return in 2025, with assets under management exceeding 70 billion yuan, making it one of the leading quantitative hedge funds in China [6][6][6] - Ctrip is under investigation for alleged monopolistic practices, with the company stating it will cooperate fully with regulatory authorities [13][13][13]

Market Overview - The market experienced a sudden drop in the afternoon after a strong morning performance, with the Hong Kong stock market recovering to close up 0.56% [1] - Trading volume increased to 340.4 billion [1] - A regulatory change raised the minimum margin requirement for margin trading from 80% to 100%, aimed at reducing leverage, but existing contracts remain unaffected [1] - Historical data suggests that similar regulatory actions have not significantly impacted market trends, indicating that this adjustment is more about tempering an overheated market [1] Economic Indicators - The U.S. core CPI for December rose by 0.2% month-on-month and 2.6% year-on-year, both below expectations [2] - The conditions for potential interest rate cuts by the Federal Reserve are becoming more favorable, despite the current data not being sufficient for immediate action [2] Gold and Silver Market - Gold prices continue to rise, with silver experiencing a significant increase, reaching a historical high of $90 [2] - The total market value of silver has surpassed $5 trillion, making it the second-largest asset globally [2] - The performance of gold mining companies, such as the increase in production capacity for Zijin Mining, is expected to contribute positively to their stock prices [2] AI and Technology Sector - The launch of a new image generation model by Zhiyuan in collaboration with Huawei marks a significant advancement in AI technology, with the stock rising nearly 19% [3] - Jefferies' report indicates that Chinese AI stocks have further upside potential due to increased capital expenditure and favorable policy signals [3] Healthcare and Pharmaceuticals - Alibaba's Qianwen app has surpassed 100 million monthly active users, indicating strong growth in the healthcare AI sector [4] - The approval of a key laboratory for multi-modal intelligent diagnosis systems highlights the ongoing advancements in medical AI applications [4][5] - The global pharmaceutical industry is increasingly recognizing Chinese innovative drug assets as essential for evaluation in mergers and acquisitions [8][9] Gaming and Entertainment - Bilibili is integrating AI technology into its marketing strategies, leading to a stock increase of over 5% [6] - The successful launch of the mobile game "Goose Goose Duck" by Kingsoft has resulted in significant user growth and engagement [6] Industrial Sector - Innovation and strong growth in the industrial AI market are reflected in the performance of companies like Innovation Qizhi, which leads in market share [5] - Sany International's recent delivery of automated port equipment signifies progress in the automation and smart construction of ports, with a revenue increase of 14.7% year-on-year [10][11] Gaming and Consumer Goods - The consumer electronics sector is seeing strong performance, with companies like Hillstone Technology reporting a profit increase of 400% to 450% [6] - The return of Haidilao's founder to management is expected to bring new expectations, resulting in a stock increase of over 9% [6] Macau Gaming Industry - Macau's gaming revenue is projected to grow significantly, with a year-on-year increase of 18% noted in early January [7] - Galaxy Entertainment is favored due to its strategic positioning in hosting major events, contributing to its stock performance [7]

Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) has seen a rise of 1.48% as of January 14, 2026, with a turnover of 2.21% and a transaction volume of 37.37 million yuan [1] - The ETF's latest scale reached 1.671 billion yuan and the latest share count reached 1.883 billion, both hitting record highs since its inception [1] - The 44th JPMorgan Healthcare Conference is being held from January 12 to 15, 2026, in San Francisco, focusing on biotechnology, biopharmaceuticals, and AI in medicine, marking it as a significant investment and trading window for the global pharmaceutical industry [1] Group 2 - Yilian Biotech announced a new exclusive licensing agreement with Roche for the YL201 project, which includes an upfront payment of $570 million and potential milestone payments [2] - Haizhi Science signed a licensing agreement with AirNexis for the HSK39004 project, with a total transaction value exceeding $1 billion, currently in Phase II clinical trials in China [2] - Zhongsheng Peptide has reached a global licensing and collaboration agreement with Novartis for an undisclosed peptide asset in the field of radioligand therapy [2] Group 3 - The Hong Kong Stock Connect Innovative Drug Index aims to reflect the operational characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect [3] - The top ten weighted stocks in the index include CSPC Pharmaceutical Group, BeiGene, CanSino Biologics, China National Pharmaceutical Group, Innovent Biologics, 3SBio, Hansoh Pharmaceutical, Kelun-Biotech, Kangzheng Pharmaceutical, and Ascentage Pharma-B [3]

Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a strong increase, reaching a peak price of 2.88% and currently up by 2.52% [1] - Key performing stocks within the ETF include China Biologic Products, BeiGene, and Hansoh Pharmaceutical, with respective increases of 5.21%, 3.53%, and 3.14% [1] - The market anticipates more international collaboration opportunities for Chinese innovative drug companies following the JPM Healthcare Conference held from January 12 to 15, 2026 [2][3] Group 2 - West Securities predicts that the Hong Kong innovative drug sector will continue to show structural trends in 2026, with accelerated BD (business development) overseas driving the convergence of drug price differences between China and the U.S. [3] - Huafu Securities emphasizes that innovation will be a clear focus in 2026, particularly in cutting-edge technology platforms such as gene therapy and small nucleic acids [3] - The top ten weighted stocks in the Hang Seng Stock Connect Innovative Drug Select Index include Kangfang Biologics, CSPC Pharmaceutical Group, BeiGene, and China Biologic Products [3]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a strong increase, reaching a peak of 2.88% and currently up by 2.52% [1][4]. Group 1: ETF Performance - The ETF's price reached a high of 0.577, with a current price of 0.569, reflecting a gain of 0.014 or 2.52% [2][6]. - The trading volume for the ETF was reported at 178,084 shares, with a turnover rate of 3.73% [6]. Group 2: Component Stocks - Notable performers among the ETF's component stocks include China Biologic Products, BeiGene, and Hansoh Pharmaceutical, with respective increases of 5.21%, 3.53%, and 3.14% [1][5]. - Conversely, the stocks of Jiujiu Bio and Ascletis Pharma showed significant declines [1][5]. Group 3: Market Expectations - The JPM Healthcare Conference, held from January 12 to 15, 2026, has generated market anticipation regarding business development (BD) transaction data from Chinese innovative pharmaceutical companies, suggesting potential for increased international collaboration [6][7]. - The approval of updated labeling for the PD-1/VEGF dual antibody by the National Medical Products Administration for Kangfang Biopharma is expected to enhance treatment options for non-small cell lung cancer, indicating significant survival benefits [6][7]. Group 4: Industry Outlook - According to Western Securities, the innovative drug sector in Hong Kong is expected to maintain a structural market trend in 2026, with accelerated BD activities narrowing the price gap between Chinese and U.S. innovative drugs, leading to substantial long-term growth potential [7]. - Huafu Securities emphasizes that innovation will be a clear focus in 2026, particularly in cutting-edge technology platforms such as gene therapy and small nucleic acids [7].